12/15/2004 4:52:17 PM
Arrowhead Research Corporation Announces Research Report on Nano Patent Portfolio
Arrowhead Research Corporation announced that CHI Research, a worldwide leader in intellectual property analysis, recently conducted a review of Arrowhead's patent portfolio. The final report stated: "In general, it appears that Arrowhead's nanotechnology IP already locks up, or is well on the way to locking up, those areas of nanotechnology that it has set out to control. Furthermore, we find that Arrowhead's entire nanotechnology patent portfolio is more broadly distributed across invention art classifications than that of its main competitors. In other words, among its main competitors, Arrowhead has the most diversified portfolio of patents in the nanotechnology space." Arrowhead has exclusive rights to 33 issued U.S. patents and, in total, over 180 U.S. and international patents and patent applications.
Arrowhead Research is a nanotechnology company structured to bring together a diverse and innovative mix of technologies, rights to a broad suite of intellectual property, and some of the most respected minds in this dynamic field. There are three strategic components to Arrowhead's business model:
- The formation or acquisition of subsidiary companies that are engaged in pursuing specific product and technology development in nanotechnology.
- The funding of nanoscience research at universities in exchange for the right to commercialize resulting intellectual property.
- The acquisition, license and sublicense of intellectual property in the field of nanotechnology.
Arrowhead Research operates three majority-owned subsidiary companies:
- Aonex Technologies, Inc., developing and commercializing semiconductor nanomaterial technology.
- Insert Therapeutics, Inc. which is developing and commercializing a proprietary drug delivery system.
- Nanotechnica, Inc., formed to develop capabilities for mass-production of a variety of different nanoscale devices and systems.
Other Headlines from Arrowhead Research Corporation ...
- Arrowhead Options Obesity-Fighting Technology from MD Anderson Cancer Center
- Arrowhead Portfolio Company, Leonardo Biosystems, Receives $2.5 Million Funding from Texas Emerging Technology Fund
- Arrowhead's Portfolio Company, Nanotope, Publishes Preclinical Data Demonstrating Cartilage Regeneration
- Arrowhead Research Corporation Subsidiary Tego Biosciences Sells IP Portfolio to Luna Innovations
- Arrowhead Increases Ownership in Carbon Nanotube-based Electronics Films Subsidiary Unidym Inc. to 70%
More Patent Headlines ...
- AdvanSource Biomaterials Announces Patent for Antimicrobial Polyurethane Resins
- Patent is Filed on Shrink Nanotechnologies’ CellAlign Advanced Tissue Engineering Platform Technology
- QD Vision Acquires Motorola Patent Portfolio Covering the Use of Quantum Dots in Display and Lighting Applications
- Shrink Nanotechnologies' Biotech R&D Group Files Patent on Rapid Prototyping System for the $2.6 Billion Biochip Market
- Brookhaven Lab Chemists Receive Patents for Fuel-Cell Catalysts
|
